ELOX - Company ID 0001035354
The table below shows Eloxx Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$5.45M | $1.20M | -$6.81M | -$9.49M | -$7.68M | -$11.92M |
| Capital expenditure | - | - | $0.00 | $11.00K | - | - |
| Investing cash flow | - | - | $11.00K | -$11.00K | - | $15.79M |
| Dividends paid | - | - | - | - | - |
Eloxx Pharmaceuticals, Inc. reported operating cash flow of -$6.33M for fiscal year 2025. That is down 34.2% from -$4.71M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$8.84M (FY 2016) to -$6.33M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $7.03M | -$865.00K | -$7.50M | $7.00M | $1.26M | -$483.00K |